Results 91 to 100 of about 4,083,428 (217)
The view that the use of serotonergic psychedelics in mental health care should always be psychotherapeutically embedded has recently been questioned. One argument against this model concerns the high costs it entails, which could limit the accessibility
Daniel Villiger
semanticscholar +1 more source
Safety pharmacology of acute mescaline administration in healthy participants
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber +4 more
wiley +1 more source
Psychedelic experiences in psychedelic-assisted therapy for depression
Psychedelics have shown promise as a treatment for depression. Although there is some debate, a popular view is that psychedelics produce their benefits in an experience-dependent manner. This is the view that a depressed person gets better, inter alia, because of the experience she has had on psychedelics.
openaire +3 more sources
ABSTRACT The issue of post‐trial responsibility is about what is owed to research participants after a clinical trial ends, who is responsible, and how long this responsibility must endure. Despite two decades of international guidance on this issue, research involving novel high‐risk interventions—such as implantable neurotechnologies—raises ...
Nathan Higgins +2 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Adolescent Psychedelic-Assisted Therapy
Amidst a growing prevalence of adolescent mental ill-health, there is a pressing need to develop effective therapeutic interventions. Despite promising results from adult trials of psychedelic-assisted therapies (P-AT), translating these interventions to adolescents presents challenges.
Bryony Insua-Summerhays, Edward Jacobs
openaire +1 more source
Abstract Neuropsychiatric presentations are common across neurological and mental health services but they are often inadequately covered by core clinical psychology and clinical neuropsychology training. Consequently, we aimed to identify components for a neuropsychiatry curriculum for clinical psychologists using a Delphi process.
Keishema Kerr +18 more
wiley +1 more source
Insurance Coverage for Psychedelic Therapy
As psychedelic-assisted therapies advance through the FDA approval pipeline, the question of who will pay for them is moving from academic to urgent. Experts project that MDMA-assisted therapy for PTSD will cost upwards of $11,000-$12,000 per course of ...
Vincent Joralemon
core +1 more source
The role of therapeutic support in psychedelic-assisted therapy: a scoping review
A scoping review of clinical trials and observational studies with the Psychedelic Assisted Therapy as the main intervention. The objectives are to describe and categorize therapeutic protocols (psychosocial procedures), to understand the role of ...
João Ariel Bonar Fernandes +3 more
core +1 more source
Table_1_The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy.docx
Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstream services are expected to offer it to selected patients.
Kathryn Forcer (11758190) +4 more
core +1 more source

